MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma
Citations Over TimeTop 10% of 2014 papers
Abstract
Therapeutic applications of microRNAs (miRNAs) in RAS-driven glioma were valuable, but their specific roles and functions have yet to be fully elucidated. Here, we firstly report that miR-143 directly targets the neuroblastoma RAS viral oncogene homolog (N-RAS) and functions as a tumor-suppressor in glioma. Overexpression of miR-143 decreased the expression of N-RAS, inhibited PI3K/AKT, MAPK/ERK signaling, and attenuated the accumulation of p65 in nucleus of glioma cells. In human clinical specimens, miR-143 was downregulated where an adverse with N-RAS expression was observed. Furthermore, overexpression of miR-143 decreased glioma cell migration, invasion, tube formation and slowed tumor growth and angiogenesis in a manner associated with N-RAS downregulation in vitro and in vivo. Finally, miR-143 also sensitizes glioma cells to temozolomide (TMZ),the first-line drug for glioma treatment. Taken together, for the first time, our results demonstrate that miR-143 plays a significant role in inactivating the RAS signaling pathway through the inhibition of N-RAS, which may provide a novel therapeutic strategy for treatment of glioma and other RAS-driven cancers.
Related Papers
- → A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme(2012)117 cited
- → 12-Cycle of Temozolomide Treatment is not Superior To 6-Cycle of Treatment in Glioblastoma Multiforme(2020)1 cited
- → 42 A novel approach using accelerated hypo-fractionation-IMRT (AH-IMRT) and temozolomide (TMZ) in patients with glioblastoma multiforme (GBM)(2006)
- → Evaluation of tolerance of Temozolomide in different strategies for management of the older person with glioblastoma(2013)
- 2. Glioblastoma再発に対しTemozolomideを使用した１例(第35回群馬脳腫瘍研究会)(2009)